Imugene Limited
IUGNF
$0.1741
-$0.0073-4.02%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 410.00K | 421.60K | -1.02M | -1.02M | 2.63M |
| Total Revenue | 410.00K | 421.60K | -1.02M | -1.02M | 2.63M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 410.00K | 421.60K | -1.02M | -1.02M | 2.63M |
| SG&A Expenses | 6.20M | 6.37M | 8.35M | 8.34M | 11.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 248.80K | 255.80K | 50.80K | 50.70K | -50.30K |
| Total Operating Expenses | 16.65M | 17.12M | 22.31M | 22.27M | 25.77M |
| Operating Income | -16.24M | -16.69M | -23.33M | -23.28M | -23.14M |
| Income Before Tax | -15.75M | -16.19M | -26.68M | -26.62M | -22.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.75M | -16.19M | -26.68M | -26.62M | -22.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.75M | -16.19M | -26.68M | -26.62M | -22.39M |
| EBIT | -16.24M | -16.69M | -23.33M | -23.28M | -23.14M |
| EBITDA | -15.81M | -16.26M | -22.50M | -22.46M | -22.53M |
| EPS Basic | -0.07 | -0.07 | -0.12 | -0.12 | -0.11 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.07 | -0.07 | -0.07 |
| EPS Diluted | -0.07 | -0.07 | -0.12 | -0.12 | -0.11 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.07 | -0.07 | -0.07 |
| Average Basic Shares Outstanding | 217.88M | 217.88M | 214.58M | 214.58M | 202.41M |
| Average Diluted Shares Outstanding | 217.88M | 217.88M | 214.58M | 214.58M | 202.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |